A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
A phase 1/2 trial of Palbociclib, Ribociclib, Abemaciclib and Everolimus in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.
Overview
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC is a phase 1/2 interventional study registered as NCT07002177 by Forward Pharmaceuticals Co., Ltd., with 196 participants planned, started 2025-06-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG and Everolimus 10 mg.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Shares Forward Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Abemaciclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Ribociclib, Abemaciclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Shares Everolimus, Ribociclib, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Shares Everolimus, Ribociclib, Abemaciclib and the tag pipeline.